467 related articles for article (PubMed ID: 15353805)
21. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
22. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
Izeradjene K; Douglas L; Delaney AB; Houghton JA
Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
[TBL] [Abstract][Full Text] [Related]
23. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.
Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S
Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142
[TBL] [Abstract][Full Text] [Related]
24. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
Suliman A; Lam A; Datta R; Srivastava RK
Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
[TBL] [Abstract][Full Text] [Related]
25. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
26. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
28. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
Ozören N; El-Deiry WS
Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
[TBL] [Abstract][Full Text] [Related]
29. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
30. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Fulda S; Wick W; Weller M; Debatin KM
Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
[TBL] [Abstract][Full Text] [Related]
31. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS
Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound.
Cheung HH; Mahoney DJ; Lacasse EC; Korneluk RG
Cancer Res; 2009 Oct; 69(19):7729-38. PubMed ID: 19773432
[TBL] [Abstract][Full Text] [Related]
33. Reduced response of prostate cancer cells to TRAIL is modulated by NFkappaB-mediated inhibition of caspases and Bid activation.
Eid MA; Lewis RW; Abdel-Mageed AB; Kumar MV
Int J Oncol; 2002 Jul; 21(1):111-7. PubMed ID: 12063557
[TBL] [Abstract][Full Text] [Related]
34. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
35. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
36. Over-expression of Smac promotes TRAIL-induced cell death in human hepatocellular carcinoma.
Okano H; Shiraki K; Inoue H; Kawakita T; Saitou Y; Enokimura N; Yamamoto N; Sugimoto K; Fujikawa K; Murata K; Nakano T
Int J Mol Med; 2003 Jul; 12(1):25-8. PubMed ID: 12792804
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
[TBL] [Abstract][Full Text] [Related]
38. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
39. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
40. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
